Growth in Baxter International's acute therapies business continued in the second quarter of 2020 largely due to demand for renal replacement therapy as the COVID-19 pandemic took hold.
On 30 July, the company reporting sales of $186m for the second quarter of 2020, representing a 40% year-over-year increase. By comparison, Baxter reported 23% growth in the first quarter of 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?